A Potential New Use for Tocilizumab: Refractory Checkpoint Inhibitor Hepatitis

Immune checkpoint inhibitors are becoming more commonly used for many forms of malignancy. With this class of medications being more heavily used, there has been an associated rise in medication-induced autoimmune hepatitis. This case involves a 35-year-old woman being treated with nivolumab/ipilimu...

Descripción completa

Detalles Bibliográficos
Autores principales: Lyles, Laine, Farmer, Reagan, Abougergi, Marwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10519460/
https://www.ncbi.nlm.nih.gov/pubmed/37753105
http://dx.doi.org/10.14309/crj.0000000000001162
Descripción
Sumario:Immune checkpoint inhibitors are becoming more commonly used for many forms of malignancy. With this class of medications being more heavily used, there has been an associated rise in medication-induced autoimmune hepatitis. This case involves a 35-year-old woman being treated with nivolumab/ipilimumab for renal cell carcinoma who developed a steroid-refractory autoimmune hepatitis.

Ejemplares similares